Aurora: Investor Presentation

Establishing EU Market Leadership European Union Population: ~465 million | Market Opportunity: ~C$98 billion GERMANY - The acquisition of Pedanios, now Aurora Deutschland, provides distinct first-mover advantage in the single largest federally legalized medical cannabis market with a population of 82+ million in Germany EU GMP certified facilities necessary for success in the EU markets Aurora currently holds a leading market share in the German medical market 70+ employees across Germany and the EU Germany has broad insurance coverage for medical cannabis, allowing for substantially higher margins and is expected to reduce margin compression over time Selected by the German Federal Institute for Drugs and Medical Devices as one of three winners in the public tender to cultivate and distribute medical cannabis in Germany Source: BMO Research. 1. Estimated to be completed by calendar H2 2019 DENMARK First LP to ship medical cannabis to Denmark. Aurora also has Aurora Nordic, a 51% owned, 1,000,000 sq ft facility being built(¹) in Odensk, along with a 100,000 sq ft retrofit facility MALTA - First LP to receive cultivation LOI issued by the Maltese authorities to date and first LP to ship medical cannabis to Malta UNITED KINGDOM - Authorities recently granted Aurora approval for its first shipment of medical cannabis into the UK from Canada ITALY - Supplying cannabis to the Italian government through Aurora Europe. First LP to complete private export from Canada in April 2018 CZECH REPUBLIC - Supplying cannabis to Czech Medical Herbs s.r.o. ("CMH"), a Czech pharmaceutical wholesaler, for distribution to pharmacies throughout the country POLAND - First LP to receive cannabis import permit from the Polish Ministry of Health PORTUGAL - Joint venture partnership with Gaia Pharm Lda. to develop facility and produce medical cannabis and derivative products AURORA 12

View entire presentation